Alzheimer Disease Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin E and Donepezil HCL (Aricept) to Delay Clinical Progression From Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD)
Verified date | June 2009 |
Source | National Institute on Aging (NIA) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
The National Institute on Aging (NIA) is launching a nationwide treatment study targeting
individuals with mild cognitive impairment (MCI), a condition characterized by a memory
deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from
both dementia and normal age-related changes in memory. Accurate and early evaluation and
treatment of MCI individuals might prevent further cognitive decline, including development
of Alzheimer's disease (AD).
The Memory Impairment Study is the first such AD prevention clinical trial carried out by
NIH, and will be conducted at 65-80 medical research institutions located in the United
States and Canada. This study will test the usefulness of two drugs to slow or stop the
conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an
investigational agent approved by the Food and Drug Administration for another use. Vitamin
E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997
study to delay important dementia milestones, such as patients' institutionalization or
progression to severe dementia, by about seven months.
Status | Completed |
Enrollment | 0 |
Est. completion date | January 2004 |
Est. primary completion date | January 2004 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 55 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Memory complaints and memory difficulties which are verified by an informant. - Abnormal memory function documented by scoring below the education adjusted cutoff on the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale - Revised (the maximum score is 25): a) less than or equal to 8 for 16 or more years of education, b) less than or equal to 4 for 8-15 years of education, c) less than or equal to 2 for 0-7 years of education. - Mini-Mental Exam score between 24 and 30 (inclusive) (Exceptions may be made for subjects with less than 8 years of education at the discretion of the project director.). - Clinical Dementia Rating = 0.5. Memory Box score must be at least 0.5. - General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer's disease cannot be made by the site physician at the time of the screening visit. - No significant cerebrovascular disease: Modified Hachinski score of less than or equal to 4. - Age between 55 and 90 (inclusive). - Permitted medications stable for at least 1 month prior to screening. In particular: a) Subjects may take stable doses of antidepressants lacking significant anticholinergic side effects (if they are not currently depressed and do not have a history of major depression within the past 2 years). b) Estrogen replacement therapy is permissible. c) Ginkgo biloba is permissible, but discouraged. - Hamilton Depression rating scale score of less than or equal to 12 on the 17-item scale. - Informant is available who has frequent contact with the subject (e.g. an average of 10 hours per week or more), agrees to monitor administration of study drug, observe for adverse events, and accompany the subject to all clinic visits for the duration of the protocol. - CT or MRI scans within 12 months prior to screening without evidence of infection, infarction, or other focal lesions and without clinical symptoms suggestive of intervening neurological disease. A lacune in a non-critical brain area which is not believed to contribute to the subject's cognitive impairment is permissible. - Adequate visual and auditory acuity to allow neuropsychological testing. - Good general health with no additional diseases expected to interfere with the study. - Normal B12, RPR, and Thyroid Function Tests or without any clinically significant abnormalities that would be expected to interfere with the study. - ECG without clinically significant abnormalities that would be expected to interfere with the study. - Subject is not pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal or surgically sterile). - Agreement not to take other vitamin supplements (including Vitamin E), multivitamins, other than those provided by the study. Exclusion Criteria: - Any significant neurologic disease other than suspected incipient Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities. - Major depression or another major psychiatric disorder as described in DSM IV within the past 2 years. - Psychotic features, agitation or behavioral problems within the last 3 months which could lead to difficulty complying with the protocol. - History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria). - History of schizophrenia (DSM IV criteria). - Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol including: a) History of systemic cancer within the last 5 years (non-metastatic skin cancers are acceptable). b) History of myocardial infarction within the past year or unstable or severe cardiovascular disease including angina or CHF with symptoms at rest. c) Clinically significant obstructive pulmonary disease or asthma. d) Clinically significant and unstable gastrointestinal disorder such as ulcer disease or a history of active or occult gastrointestinal bleeding within two years. e) Clinically significant laboratory test abnormalities on the battery of screening tests (hematology, prothrombin time, chemistry, urinalysis, ECG). f) Insulin-requiring diabetes or uncontrolled diabetes mellitus. g) Uncontrolled hypertension (systolic BP greater than 170 or diastolic greater than 100). h) History of clinically significant liver disease, coagulopathy, or vitamin K deficiency within the past 2 years. - Medications a) Use of centrally active beta-blockers, narcotics, methyldopa and clonidine within 4 weeks prior to screening. b) Use of anti-Parkinsonian medications (e.g. Sinemet, amantadine, bromocriptine, pergolide and selegiline) within 2 months prior to screening. c) Use of neuroleptics or narcotic analgesics within 4 weeks prior to screening. d) Use of long-acting benzodiazepines or barbituates within 4 weeks prior to screening. e) Use of short-acting anxiolytics or sedative hypnotics more frequently than 2 times per week within 4 weeks prior to screening (note: sedative agents should not be used within 72 hours of screening). f) Initiation or change in dose of an antidepressant lacking significant cholinergic side effects within the 4 weeks prior to screening (use of stable doses of antidepressants for at least 4 weeks prior to screening is acceptable). g) Use of systemic corticosteroids within 3 months prior to screening. h) Medications with significant cholinergic or anticholinergic side effects (e.g. pyridostigmine, tricyclic antidepressants, meclizine, and oxybutynin) within 4 weeks prior to screening. i) Use of anti-convulsants (e.g. Phenytoin, Phenobarbital, Carbamazepine) within 2 months prior to screening. j) Use of warfarin (Coumadin) within 4 weeks prior to screening. - Vitamin Supplements a) Use of vitamin supplements other than standard multivitamin included as part of the treatment intervention used in this protocol within 2 weeks prior to screening. - Any prior use of any FDA approved medications for the treatment of Alzheimer's disease (e.g. tacrine, donepezil, or other newly approved medications). - Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening. - Subjects who, in the investigator's opinion, will not comply with study procedures. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | University of Calgary | Calgary | Alberta |
Canada | Fredericton Medical Clinic | Fredericton | New Brunswick |
Canada | Geriatric Medicine Research Group | Halifax | Nova Scotia |
Canada | St. Joseph's Health Center | London | Ontario |
Canada | Jewish General Hospital Memory Clinic | Montreal | Quebec |
Canada | Elizabeth Bruyere Centre | Ottawa | Ontario |
Canada | Sunnybrook Health Science Center | Toronto | Ontario |
Canada | University of British Columbia | Vancouver | British Columbia |
Canada | McGill Centre for Studies in Aging | Verdun | Quebec |
United States | Univ. of New Mexico | Albuquerque | New Mexico |
United States | University of Michigan | Ann Arbor | Michigan |
United States | Emory University | Atlanta | Georgia |
United States | Augusta VA Medical Center | Augusta | Georgia |
United States | Johns Hopkins University | Baltimore | Maryland |
United States | Southwestern Vermont Medical Center | Bennington | Vermont |
United States | Baumel-Eisner Neuromedical Institute, Boca Raton | Boca Raton | Florida |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Maimonides Medical Center | Brooklyn | New York |
United States | Clinical Neuroscience Research Unit | Burlington | Vermont |
United States | Northwestern University | Chicago | Illinois |
United States | Rush Presbyterian St. Luke's Medical Center | Chicago | Illinois |
United States | University Hospitals of Cleveland | Cleveland | Ohio |
United States | Duke University Medical Center | Durham | North Carolina |
United States | Baumel-Eisner Neuromedical Institute, Ft. Lauderdale | Ft. Lauderdale | Florida |
United States | Baylor College of Medicine | Houston | Texas |
United States | Indiana University | Indianapolis | Indiana |
United States | UC Irvine Institute for Brain Aging and Dementia | Irvine | California |
United States | Mayo Clinic Jacksonville | Jacksonville | Florida |
United States | University of Kansas Medical Center | Kansas City | Kansas |
United States | Memory Disorders Institute | Lakehurst | New Jersey |
United States | University of Nevada | Las Vegas | Nevada |
United States | Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire |
United States | University of Kentucky | Lexington | Kentucky |
United States | University of California, Los Angeles | Los Angeles | California |
United States | University of Southern California | Los Angeles | California |
United States | Marshfield Clinic | Marshfield | Wisconsin |
United States | East Bay Institute | Martinez | California |
United States | Baumel-Eisner Neuromedical Institute, MiamiBeach | Miami Beach | Florida |
United States | Wein Center | Miami Beach | Florida |
United States | University of Minnesota | Minneapolis | Minnesota |
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
United States | Yale University | New Haven | Connecticut |
United States | Columbia University | New York | New York |
United States | Mount Sinai Medical Center | New York | New York |
United States | NYU Medical Center | New York | New York |
United States | Medical University of South Carolina | North Charleston | South Carolina |
United States | Nathan S. Kline Institute for Psychiatric Research | Orangeburg | New York |
United States | Brown University | Pawtucket | Rhode Island |
United States | MCP Hahnemann | Philadelphia | Pennsylvania |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | Barrow Neurological Group | Phoenix | Arizona |
United States | University of Pittsburgh | Pittsburgh | Pennsylvania |
United States | University of Miami | Port Charlotte | Florida |
United States | Oregon Health Sciences University | Portland | Oregon |
United States | Princeton Biomedical Research, PA | Princeton | New Jersey |
United States | Mayo Clinic | Rochester | Minnesota |
United States | University of Rochester | Rochester | New York |
United States | Sutter Institute for Medical Research | Sacramento | California |
United States | Affiliated Research Instiute | San Diego | California |
United States | University of California, San Diego | San Diego | California |
United States | University of California, San Francisco | San Francisco | California |
United States | University of Washington | Seattle | Washington |
United States | Southern Illinois University | Springfield | Illinois |
United States | Washington University | St. Louis | Missouri |
United States | SUNY Stony Brook | Stony Brook | New York |
United States | ClinSearch, Inc. | Summit | New Jersey |
United States | University of South Florida | Tampa | Florida |
United States | Princeton Biomedical - Toms River | Toms River | New Jersey |
United States | University of Arizona | Tucson | Arizona |
United States | Alzheimer's Research Corp. | West Long Branch | New Jersey |
United States | Premiere Research Institute | West Palm Beach | Florida |
United States | Burke Medical Research Institute | White Plains | New York |
Lead Sponsor | Collaborator |
---|---|
National Institute on Aging (NIA) | Alzheimer's Disease Cooperative Study (ADCS) |
United States, Canada,
Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR Jr, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal L — View Citation
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG. Aging, memory, and mild cognitive impairment. Int Psychogeriatr. 1997;9 Suppl 1:65-9. — View Citation
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998 Jan;50(1):136-45. — View Citation
Rubin EH, Morris JC, Grant EA, Vendegna T. Very mild senile dementia of the Alzheimer type. I. Clinical assessment. Arch Neurol. 1989 Apr;46(4):379-82. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |